

H.P. Acthar® Gel Reference Bibliography

This bibliography contains verifiable peer-reviewed manuscripts and abstracts on the use of Acthar Gel, as well as publications supported by Mallinckrodt that relate to Acthar directly or indirectly. Human and preclinical studies, reports and reviews are included and, where available, links to PubMed are provided. Updated November 2015

Nephrology

1. Anwar S, Larson DS, Naimi N, et al. A case report of adrenocorticotrophic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring. *Front Med (Lausanne)*. 2015;2:13. [Link](#)
2. Arif H, Ellie K, Monalisa J. "Repository ACTH". Novel therapy in treatment of resistant nephrotic syndrome [NKF abstract 23]. *Am J Kidney Dis*. 2013;61(4):A21. [Link](#)
3. Beck LH, Fervenza FC, Bomback AS, et al. Treatment of membranous nephropathy with adrenocorticotrophic hormone (ACTH) gel: Correlation of anti-PLA2R and disease activity [ERA-EDTA abstract SAP294]. *Nephrol Dial Transplant*. 2012;27(suppl 2):ii416-ii417
4. Berg AL. Plasma cortisol levels after natural ACTH 1-39 and syntetic ACTH 1-24 in humans [NKF abstract 39]. *Am J Kidney Dis*. 2013;61(4):A25
5. Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH) gel. *Drug Des Devel Ther*. 2011;5:147-153. [Link](#)
6. Bomback AS, Canetta PA, Beck LH, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotrophic hormone gel: A prospective trial. *American Journal of Nephrology*. 2012;36(1):58-67. [Link](#)
7. Bonilla MA, Parada XF, Henriquez MA. A case series on the treatment of nephrotic syndrome with natural adrenocorticotrophic hormone gel in an office setting [ASN abstract PUB219] *J Am Soc Nephrol*. 2015;26(suppl):937A. [Link](#)
8. Faizan MK, Ruchir SP. Successful remission of treatment-resistant minimal change disease with adrenocorticotrophic hormone gel [ASN abstract PUB135]. *J Am Soc Nephrol*. 2013;24(suppl):905A-906A
9. Gaurav K, Gera M. Experience with Acthar for treatment of nephrotic range proteinuria of different etiologies. A case series [NKF abstract 103]. *Am J Kidney Dis*. 2013;61(4):A41. [Link](#)
10. Higgins P, Young D. Inhibitory effects of Acthar Gel in the passive Heymann nephritis model [ASN abstract FR-PO338]. *J Am Soc Nephrol*. 2014;25(suppl):448A
11. Hladunewich MA, Cattran D, Beck LH, et al. A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. *Nephrology*. 2014;29(8):1570-1577. [Link](#)
12. Hogan J, Bomback AS, Mehta K, et al. Treatment of idiopathic FSGS with adrenocorticotrophic hormone gel. *Clinical Journal of the American Society of Nephrology*. 2013;8(12):2072-2081. [Link](#)
13. Khastgir A, Teehan GS. Maintenance of proteinuria treatment response to H.P. Acthar Gel® in patients with nephrotic syndrome: A follow-up case series [ASN abstract PUB212] *J Am Soc Nephrol*. 2015;26:936A. [Link](#)
14. Khastgir A. H.P. Acthar Gel treatment in patients with nephrotic syndrome: A retrospective case series [MON-248]. Poster Presented at: *ISN World Congress of Nephrology*, March 13-17, 2015; Cape Town, South Africa. 2015
15. Khastgir A, Mijovic-Das S. H.P. Acthar® Gel in patients with IGA nephropathy, membranous lupus nephritis and minimal change disease: A retrospective case series [NKF abstract SCM15]. *Am J Kidney Dis*. 2015;65(4):A49
16. Koppula S, Amy NS, Barry RG. Reemergence of adrenocorticotropin hormone as novel therapy for focal segmental glomerulosclerosis [ASN abstract SA-PO1031]. *J Am Soc Nephrol*. 2012;23(suppl):879A
17. Lafayette RA, Root C, Metha K. Adrenocorticotropin hormone (ACTH) for the treatment of primary focal glomerulosclerosis (FSGS) [NKF abstract 140]. *Am J Kidney Dis*. 2012;59(4):B49

18. Lieberman K. A pooled analysis of early use of adrenocorticotrophic hormone in nephrotic syndrome [ASN abstract PUB254]. *J Am Soc Nephrol*. 2014;25(suppl):952A
19. Lieberman KV. Adrenocorticotrophic hormone for steroid-resistant and oral steroid-intolerant children with minimal change nephrotic syndrome. *J Clin Ped Nephrol*. 2014;2(2):1-4
20. Lieberman KV, Pavlova-Wolf A. Adrenocorticotrophic hormone therapy for the treatment of Idiopathic Nephrotic Syndrome in children and young adults: A systematic review of early clinical studies [ESPN abstract P-391]. *Pediatr Nephrol*. 2015;30(1694).
21. Madan A, Teehan GS, Stankovic AK. Treatment response to H.P. Acthar Gel in patients with idiopathic focal segmental glomerulosclerosis and idiopathic membranous nephropathy: A retrospective case series [ASN abstract TH-PO437]. *J Am Soc Nephrol*. 2014;25(suppl):206A
22. Madan A. Repository corticotropin injection in a patient presenting with focal segmental glomerulosclerosis, rheumatoid arthritis, and optic neuritis: A case report. *Int J Gen Med*. 2015;8:119-124
23. Madan A, Milward AS, Khastgir A. Treatment of nephrotic syndrome with Acthar Gel: A retrospective case series [NKF abstract 227]. *Am J Kidney Dis*. 2014;63(5):A75
24. Marayati F. Long-term H.P. Acthar® Gel treatment of relapsing idiopathic membranous glomerulopathy: A case study [ASN abstract PUB206]. *J Am Soc Nephrol*. 2015;26(suppl):934A. [Link](#)
25. McHugh PP, Muhammad AM, Asif AS, Muhammad SY, Tim ET. Treatment of post-transplant immunosuppression resistant focal segmental glomerulosclerosis with adrenocorticotrophic gel [ASN abstract FR-PO1135]. *J Am Soc Nephrol*. 2013;24(suppl):624A
26. Melhem AY, Schmitz P. Single center experience with ACTH for the treatment of resistant nephrotic syndrome [ASN abstract SA-PO677]. *J Am Soc Nephrol*. 2013;24(suppl):783A-784A
27. Meliambro K, Sharma S, Campbell KN. Treatment-refractory histologic tip-variant FSGS in a patient with systemic lupus erythematosus [NKF abstract 68]. *Am J Kidney Dis*. 2014;63(5):A35
28. Mittal T, Dedhia P, Roy-Chaudhury P, et al. Complete remission of post-transplantation recurrence of focal segmental glomerulosclerosis with the use of adrenocorticotrophic hormone gel: Case report. *Transplant Proc*. 2015;47(7):2219-2222. [Link](#)
29. Nguyen V, El-Meanawy A. ACTH a novel treatment for IgA nephropathy [CSCTR/MWAFMR abstract 104]. *J Investig Med*. 2014;62(4):719-720
30. Patel AB, Markell MS. Use of ACTH gel in a patient with progressive nephrotic syndrome secondary to transplant glomerulopathy (TG) [ASN abstract TH-PO1140]. *J Am Soc Nephrol*. 2012;23(suppl):365A
31. Shirsat PD, Habib SY. Use of ACTH gel in a patient with progressive nephrotic syndrome secondary to transplant glomerulopathy (TG) [ASN FR-PO1088]. *J Am Soc Nephrol*. 2013;24(suppl):613A
32. Sim J, Batech M, Hever A, et al. Distribution of glomerulonephritis among an ethnically diverse United States population [ASN abstract SA-PO890]. *J Am Soc Nephrol*. 2014;25(suppl):845A
33. Tan M, Maybel M, Yap L,W. Use of ACTH gel (Acthar) as rescue therapy for transplant glomerulopathy (TG) in two kidney transplant recipients: Short and long term follow-up [ASN abstract SA-PO768]. *J Am Soc Nephrol*. 2014;25(suppl):814A
34. Tumlin JA, Galphin CM, Rovin BH. Steroid resistant nephrotic syndrome: A prospective, open label study of the safety and efficacy of combination tacrolimus and ACTHar gel therapy [ASN abstract FR-PO434]. *J Am Soc Nephrol*. 2015;26(suppl):455A. [Link](#)
35. Tumlin JA, Galphin CM, Rovin BH. Advanced diabetic nephropathy with nephrotic range proteinuria: Long- term efficacy of subcutaneous adrenocorticotrophic hormone (ACTH) therapy on proteinuria and urinary vascular endothelial growth factor (VEGF) levels [ASN abstract TH-OR073]. *J Am Soc Nephrol*. 2011;22(suppl):18A
36. Tumlin JA. Safety and efficacy of Acthar Gel (ACTH) on albuminuria and progression of diabetic nephropathy in patients with nephrotic range proteinuria: A randomized prospective study [ASN abstract SA-PO2471]. *J Am Soc Nephrol*. 2010;21(suppl):678A

37. Vasin D. Partial remission of fibrillary glomerulonephritis with crescentic and necrotizing features treated with H.P. Acthar® Gel [NKF abstract 290]. *Am J Kidney Diseases*. 2015;65(4):A87
38. Watson MJ. Membranous glomerulopathy and treatment with Acthar®: A case study. *Int J Nephrol Renovasc Dis*. 2013;6:229-232. [Link](#)
39. Welik RA. Adrenocorticotrophic hormone therapy for idiopathic glomerulonephritis: 6-week interim data from an ongoing, 6-month trial [ASN abstract PUB712]. *J Am Soc Nephrol*. 2012;23(suppl):1051A
40. Wetmore JB, Haifeng G, Gilbertson DT. Prevalence of glomerulonephritis in the U.S. Medicare population [ASN abstract FR-PO906]. *J Am Soc Nephrol*. 2014;25(suppl):579A.

Neurology

41. Alexander L, Cass LJ, Enders M, Sarai K. Adrenocortical response to high dosage ACTH therapy in patients with multiple sclerosis. *Confin Neurol*. 1966;28:1-17. [Link](#)
42. Alexander L, Cass LJ. The present status of ACTH therapy in multiple sclerosis. *Ann Intern Med*. 1963;58:454-471. [Link](#)
43. Alexander L, Cass LJ. Significance of dosage in ACTH therapy of multiple sclerosis. *Transactions of the American Neurological Association*. 1963;88:184-185. [Link](#)
44. Amezcua L, Axtell R, Cen S, et al. Pilot study of monthly pulse adrenocorticotrophic hormone (ACTH) or methylprednisolone as an add-on therapy to beta interferons for long-term treatment of multiple sclerosis [ECTRIMS abstract 1097]. *Mult Scler*. 2013;19(suppl 1):514-515
45. Arrat H, Lukas TJ, Siddique T. ACTH (Acthar Gel) reduces toxic SOD1 protein linked to amyotrophic lateral sclerosis in transgenic mice: A novel observation. *PLoS One*. 2015;10(5):e0125638. [Link](#)
46. Bailey RO, Sprague CA, Heim RR, Nguyen VA. Use of Acthar Gel for MS exacerbations during Natalizumab induction and maintenance [CMSC/ACTRIMS abstract DX11]. *Int J MS Care*. 2013;15(suppl 3):83
47. Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: A prospective, randomized, blinded study. *Pediatrics*. 1996;97(3):375-379. [Link](#)
48. Bell S, Vincent J, Hammock V, et al. A comparison of the safety/tolerability and pharmacodynamics of Acthar Gel and methylprednisolone with regimens utilized for the treatment of MS exacerbations [AAN abstract P2.207]. *Neurology*. 2014;82(suppl 10):P2.207
49. Berkovich RR, Maura F, Dawood S. Adrenocorticotrophic hormone treatment of multiple sclerosis exacerbations [CMSC/ACTRIMS abstract DX66]. *Int J MS Care*. 2012;14(suppl 2):66
50. Butterfield T, Maquera VA. Preventing new enhancing lesions and relapses after discontinuing Tysabri [CMSC/ACTRIMS abstract DX14]. *Int J MS Care*. 2013;15(suppl 3):84
51. Cusick MF, Libbey JE, Oh L, Jordan S, Fujinami RS. Acthar Gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis. *Autoimmunity*. 2015;48(4):222-230. [Link](#)
52. Gold LS, Schepman P, Niewoehner J, Philbin M, Hansen R. Healthcare resource use and costs of adrenocorticotrophic hormone in relapses of Multiple Sclerosis [WCI abstract B036]. *Inflamm Res*. 2015; 64(suppl 2): S116. [Link](#)
53. Hansen R, Gold L, Schepman P, Niewoehner J, Philbin M. Economic consequences of early versus late use of adrenocorticotrophic hormone therapy in infantile spasms [WCI abstract LB10]. Late-breaker poster presented at *World Congress of Inflammation Meeting*; August 8-12, 2015; Boston, MA. 2015. [Link](#)
54. Hrachovy RA, Frost JD, Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. *J Pediatr*. 1994;124(5 Pt.1):803-806. [Link](#)
55. Hrachovy RA, Frost JD, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. *J Pediatr*. 1983;103(4):641-645. [Link](#)

56. Hrachovy RA, Frost JD, Kellaway P, Zion T. A controlled study of ACTH therapy in infantile spasms. *Epilepsia*. 1980;21(6):631-636. [Link](#)
57. Hussain SA, Shinnar S, Kwong G, et al. Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotrophic hormone. *Epilepsia*. 2014;55(1):103-107. [Link](#)
58. Javed A, Berkovich R, Hendin B, Miller A, Tornatore C. Use of patient case scenarios to assess current practice patterns of MS relapse assessment and treatment among MS specialists in the United States [ECTRIMS abstract P671]. *Mult Scler*. 2015; 23(sup 11): 329
59. Knupp K, Wirrell E, Berg A, Khan S. The national infantile spasms consortium (NISC), A US multicenter initiative to improve treatment and outcomes of infantile spasms: Etiologies, initial therapies and early follow up [AES abstract 1.149]. *Epilepsy Curr*. 2013;14(suppl 1):68-69
60. Kossoff EH, Hedderick EF, Turner Z, Freeman JM. A case-control evaluation of the ketogenic diet versus ACTH for new-onset infantile spasms. *Epilepsia* 49 (9):1504 -9 ,. 2008. [Link](#)
61. Kutz CF. Repository corticotropin injection relapse treatment in patients with multiple sclerosis and diabetes [ECTRIMS abstract EP1353]. *Mult Scler*. 2015; 23(sup 11): 708
62. Lehrer GM. Treatment of MS with Acthar Gel-clinical experience and case presentation [ANA abstract T1819]. *Ann Neurol*. 2012;72(suppl 16):S114
63. Lisak RP, Nedelkoska L, Benjamins JA. Melanocortin 4 receptors on oligodendrocytes and oligodendrocyte precursors signal ACTH protection from in vitro death induced by mechanisms involved in cell damage in multiple sclerosis.[ECTRIMS abstract P579]. *Mult Scler*. 2015;23(11 suppl 1):273,
64. Lisak R, Nedelkoska L, Benjamins J. ACTH1-39 protection of oligodendrocytes from damage relevant to multiple sclerosis involves both direct and indirect mechanisms. [AAN abstract P2.189]. *Neurology*. 2015;84(suppl 14):P2.189
65. Lukas T, Arrat H, Siddique T. Etiology-based drug discovery is a route for new amyotrophic lateral sclerosis (ALS) therapeutics [SFN abstract 53.17/H14]. Poster Presented at: *Society for Neuroscience Annual Meeting*, October 17-21 2015, Chicago, IL. 2015.
66. Molitor RE, Stewart J. Home intravenous administration of adrenocorticotrophic hormone in patients with multiple sclerosis. *J Intraven Nurs*. 1988;11(4):249-251. [Link](#)
67. Mytinger JR, Weber A, Heyer GL. The response to ACTH is determined early in the treatment of infantile spasms [AES abstract 3.144]. *Epilepsy Curr*. 2014;14(suppl 1):360
68. Mytinger JR, Weber A, Heyer GL. The response to ACTH is determined early in the treatment of infantile spasms. *Epileptic Disord*. 2015;17(1):52-57. [Link](#)
69. Napoli S. ACTH gel in the treatment of multiple sclerosis exacerbation: A case study. *Int Med Case Rep J*. 2015;2015(8):23-27. [Link](#)
70. Nickerson M, Cofield SS, Tyry T, Salter AR, Cutter GR, Marrie RA. Impact of multiple sclerosis relapse: The NARCOMS participant perspective. *Mult Scler Relat Disord*. 2015;4(3):234-240. [Link](#)
71. Partikian A, Mitchell WG. Major adverse events associated with treatment of infantile spasms. *J Child Neurol*. 2007;22(12):1360-1366. [Link](#)
72. Pauli L, O'Neil R, Ybanez M, Livingston S. Minor motor epilepsy. Treatment with corticotropin (ACTH) and steroid therapy. *JAMA*. 1960;174:1408-1412. [Link](#)
73. Pranzatelli MR, Tate ED, McGee NR, et al. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS. *J Neuroimmunol*. 2012;243(1-2):81-88. [Link](#)
74. Pranzatelli MR, Tate ED, Verhulst SJ, et al. Pediatric dosing of Rituximab revisited: Serum concentrations in opsoclonus-myoclonus syndrome. *J Pediatr Hematol Oncol*. 2010;32(5):e167-e172. [Link](#)
75. Pranzatelli MR, Tate ED, Crowley JM, Toennies B, Creer M. Neurometabolic effects of ACTH on free amino compounds in opsoclonus-myoclonus syndrome. *Neuropediatrics*. 2008;39(3):164-171. [Link](#)
76. Pranzatelli MR, Chun KY, Moxness M, Tate ED, Allison TJ. Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: Effect of therapy. *Pediatr Neurol*. 2005;33(2):121-126. [Link](#)
77. Pranzatelli MR, Huang Y-, Tate E, et al. Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. *Mov Disord*. 1998;13(3):522-528. [Link](#)

78. Riser ES, Han J, Denney T, Steele MB. A comprehensive analysis of relapse in multiple sclerosis. Poster Presented at: *Consortium of the Multiple Sclerosis Centers Annual Meeting*, May 27-30 2015; Indianapolis, IN. 2015
79. Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report. *Neurology*. 1970;20(5):1-59. [Link](#)
80. Ross AP, Halper J, Harris CJ. Assessing relapses and response to relapse treatment in patients with multiple sclerosis: A nursing perspective. *Int J MS Care*. 2012;14(3):148-159. [Link](#)
81. Ross DL. Suppressed pituitary ACTH response after ACTH treatment of infantile spasms. *J Child Neurol*. 1986;1(1):34-37. [Link](#)
82. Ryan N, Coryell J, Nickels K, Mytinger J, Knupp K. The national infantile spasms consortium (NISC): Moving towards standardization of care and improved treatment and outcomes in infantile spasms [AES abstract 3.223]. *American Epilepsy Society Annual Meeting*. 2014
83. Simsarian JP, Saunders C, Smith DM. Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotrophic hormone gel for acute exacerbations of multiple sclerosis: A prospective, randomized, open-label pilot trial. *Drug Design*. 2011;5:381-389. [Link](#)
84. Snead III OC, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. *Neurology*. 1983;33(8):966-970. [Link](#)
85. Snead OC,III. Treatment of infantile spasms. *Pediatr Neurol*. 1990;6(3):147-150. [Link](#)
86. Snead OC,III, Benton JW, Hosey LC, et al. Treatment of infantile spasms with high-dose ACTH: Efficacy and plasma levels of ACTH and cortisol. *Neurology* 39. 1989;39(8):1027-1031. [Link](#)
87. Tate ED, Pranzatelli MR, Verhulst SJ, et al. Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. *Journal of Child Neurology*. 2012;27(7):875-884. [Link](#)
88. Taylor JB, Young WO, Rutar T. Posterior subcapsular cataracts in children receiving adrenocorticotrophic hormone (ACTH) for infantile spasms. *J Child Neurol*. 2010;25(8):1017-1019. [Link](#)
89. Wang J, Wang J, Zhang Y, et al. Proteomic analysis of adrenocorticotrophic hormone treatment of an infantile spasm model induced by N-methyl-D-aspartic acid and prenatal stress. *PLoS One*. 2012;7(9):e45347. [Link](#)
90. Waternberg N. Infantile spasms: Treatment challenges. *Curr Treat Options Neurol*. 2012;14:322-331. [Link](#)
91. Williamson A, Smrtka J, Flemming Tracy T, et al. Assessing relapse in multiple sclerosis (ARMS) questionnaire: Pilot study[ECTRIMS abstract DX59]. *Mult Scler*. 2013;15(suppl 3):329-105
92. Wray CD, Benke TA. Effect of price increase of adrenocorticotrophic hormone on treatment practices of infantile spasms. *Pediatr Neurol*. 2010;43:163-166. [Link](#)

Ophthalmology

93. Bowden AN, Bowden PM, Friedmann AI, Perkin GD, Rose FC. A trial of corticotrophin gelatin injection in acute optic neuritis. *Journal of Neurology, Neurosurgery & Psychiatry*. 1974;37(8):869-873. [Link](#)
94. Eadie S, Thompson M. Kerato-conjunctivitis sicca treated with cortisone and ACTH. *Br J Ophthalmol*. 1955;39(2):90-97. [Link](#)
95. Thorpe HE. ACTH and cortisone in ocular trauma in eye surgery: A preliminary report. *Proceedings of the Second Clinical ACTH Conference*. 1951;2(25):340-361

Pulmonology

96. Barney EJ, Baughman R. Acthar Gel for refractory sarcoidosis. Poster presented at: *Combined WASOG BAL Meeting*; October 12, 2014; Kusadasi, Turkey. 2014

97. Baughman R, Fernandez-Ulloa M, Shipley R, Thompson F, Lower E. Acthar Gel for chronic pulmonary sarcoidosis: Role of positive emission tomography in initial assessment and in response to therapy [Chest abstract]. *Chest*. 2015;148(4):392A.
98. Baughman RP, Lower EE, Lanier O'Hare, Barney JB. Acthar Gel for refractory sarcoidosis [ATS abstract A3743]. *Am J Respir Crit Care Med*. 2015;191(suppl):A3743-A3743
99. McGuire SA, Tomasovic JJ, Stevens EA. Improvement with corticotropin of relapsing central nervous system sarcoidosis during prednisone therapy: Case report. *Mil Med*. 1983;148(5):419-420. [Link](#)
100. Solomons B. Sarcoidosis; an aetiological and therapeutic appraisal. *Ir J Med Sci*. 1956;369:417-421. [Link](#)

Rheumatology

101. Aggarwal R, Marder G, Loganathan P, et al. Efficacy and safety of adrenocorticotrophic hormone gel (Acthar Gel®) in refractory dermatomyositis or polymyositis [ACR/ARHP abstract 2363]. *Arthritis Rheumatol*. 2015;67(suppl 10). [Link](#)
102. Bacon PA, Daly JR, Myles AB, Savage O. Hypothalamo-pituitary-adrenal function in patients on long-term adrenocorticotrophin therapy. *Annals of the Rheumatic Diseases*. 1968;27(1):7-13. [Link](#)
103. Bitensky L, Butcher RG, Johnstone JJ, Chayen J. Effect of glucocorticoids on lysosomes in synovial lining cells in human rheumatoid arthritis. *Ann Rheum Dis*. 1974;33(1):57-61. [Link](#)
104. Brown AN. Adrenocorticotrophic hormone gel in patients with refractory rheumatoid arthritis: A case series. *Int J Clin Rheumtol*. 2015:[published online: September 28, 2015].
105. Carey RA., Harvey AM., Howard JE. The effect of adrenocorticotrophic hormone (ACTH) and cortisone on the course of disseminated lupus erythematosus and peri-arteritis nodosa. *Bull Johns Hopkins Hosp*. 1950;87(5):425-460. [Link](#)
106. Carter ME, James VH. Effect of corticotrophin therapy on pituitary-adrenal function. *Ann Rheum Dis*. 1970;29(1):73-80. [Link](#)
107. Clark WS, Tønning HO, Kulka JP, Bauer W. Observations on the use of cortisone and ACTH in rheumatoid arthritis. *N Engl J Med*. 1953;249(16):635-642. [Link](#)
108. Daly JR, Fletcher MR, Glass D, Chambers DJ, Bitensky L, Chayen J. Comparison of effects of long-term corticotrophin and corticosteroid treatment on responses of plasma growth hormone, ACTH, and corticosteroid to hypoglycaemia. *Br Med J*. 1974;2(5918):521-524. [Link](#)
109. Decker D, Furie R, Li D, Mathura E, Becker PM. Plasma Soluble Vascular Adhesion Molecule-1 (sVCAM-1) as an exploratory marker of response to therapy in patients with persistently active systemic lupus erythematosus (SLE), [Int Congress SLE P4.25] *Clin Exp Rheum*. 2015;33(3 suppl 90): S34 [Link](#)
110. Decker D, Higgins P, Bendele A, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) attenuates established collagen-induced arthritis when used alone or as adjuvant therapy with Etanercept (Enbrel®) [AAI abstract THER5P.902]. *J Immunol*. 2015;194(suppl 1):139.4-139.4
111. Donnelly P, Cooke D. A study of the combined effect of ACTH(gel) and D-penicillamine on the functional disability of patients with rheumatoid disease. *J Rheumatol*. 1982;9(6):867-872. [Link](#)
112. Fiechtner JJ, Montroy T, June J, Huyhn-Duc J. A single-site, investigator-initiated, open-label trial of the adrenocorticotrophic hormone analog H.P. Acthar Gel (repository corticotropin injection) among subjects with active systemic lupus erythematosus [Int Congress SLE abstract P4.20] *Clin Exp Rheum*. 2015;33(3 Suppl 90): S32 [Link](#)
113. Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotrophic hormone: a single-site, open-label trial. *Lupus*. 2014;23(9):905-912. [Link](#)
114. Friedman M, Marshall-Jones P, Ross EJ. Cushing's syndrome: Adrenocortical hyperactivity secondary to neoplasms arising outside the pituitary-adrenal system. *Q J Med*. 1966;35(138):193-214. [Link](#)

115. Furie R, Das M, Li D, Coffie J, Smythe S, Mathura E, Becker, PM. H.P. Acthar Gel (Acthar) attenuates disease activity in patients with persistently active systemic lupus erythematosus (SLE) requiring corticosteroids. [Int Congress SLE P4.13]. *Clin Exp Rheum*. 2015;33(3 suppl 90): S31, [Link](#)
116. Furie R, Das M, Li D, Smythe S, Mathura E, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) attenuates disease activity in patients with persistently active systemic lupus erythematosus (SLE) requiring corticosteroids [ACR abstract 727]. *Arthritis Rheumatol*. 2015; 67 (suppl 10). [Link](#)
117. Gaylis NB, Needell S, Sagliani J. The effect of adrenocorticotropin gel (HP Acthar Gel) in combination with MTX in newly diagnosed RA patients from a clinical and structural perspective [ACR/ARHP abstract 2732]. *Arthritis Rheumatol*. 2015;67(suppl 10). [Link](#)
118. Gaylis N, Needell S, Sagliani J. The effect of corticotropin (ACTH 80 units weekly or biweekly) in combination with MTX in newly diagnosed RA patients from a clinical and structural perspective as measured by a CDAI score and osteitis, synovitis, and erosions on MRI [EULAR abstract AB0503]. *Ann Rheum Dis*. 2015;74(suppl 2):1066-1067
119. Gillhespy RO. The evaluation of long-acting ACTH in the treatment of chronic rheumatoid arthritis. *Br J Clin Pract*. 1963;17:721-723. [Link](#)
120. Gillis TM, Crane M, Hinkle C, Wei N. H.P. Acthar® Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic therapies with different modes of action [EULAR abstract AB0502]. *Ann Rheum Dis*. 2015;74(suppl 2):1066-1066
121. Glass D, Daly JR. Development of antibodies during long-term therapy with corticotrophin in rheumatoid arthritis. I. porcine ACTH. *Ann Rheum Dis*. 1971;30(6):589-592. [Link](#)
122. Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. *Arch Intern Med*. 1950;85(4):545-666. [Link](#)
123. Levine T. Acthar in dermatomyositis and polymyositis treatment registry: An interim analysis.[AAN abstract P7.065]. *Neurology*. 2015;84(suppl 14):P7.065
124. Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotrophic hormone gel: A retrospective case series. *Drug Des Devel Ther*. 2012;6:133-139. [Link](#)
125. Meliambro K, Sharma S, Campbell KN. Treatment-refractory FSGS in a patient with systemic lupus erythematosus [ASN abstract FR-PO649]. *J Am Soc Nephrol*. 2014;25(suppl):206A
126. Nelson JK, Mackay JS, Sheridan B, Weaver JA. Intermittent therapy with corticotrophin. *Lancet*. 1966;2(7454):78-83. [Link](#)
127. Nelson SD, Mackay JS, Sheridan B, Weaver JA. Intermittent corticotrophin therapy study of lymphocyte transformation in vitro in rheumatoid arthritis. *Ann Rheum Dis*. 1969;28(5):524-528. [Link](#)
128. Pegram SB. The efficacy and tolerability of H.P. Acthar® Gel (repository corticotropin injection) for the treatment of systemic lupus erythematosus [EULAR abstract AB0531]. *Ann Rheum Dis*. 2015;74(suppl 2):1077-1078
129. Savage O, Davis PS, Chapman L, Wickings J, Robertson JD, Copfman WS. Corticotrophin (ACTH) in rheumatoid arthritis. *Ann Rheum Dis*. 1959;18:100-110. [Link](#)
130. Wedgwood RJ, Janeway CA. Serum complement in children with collagen diseases. *Pediatrics*. 1953;11(6):569-581. [Link](#)
131. West HF. Purified ACTH gel control of therapy in rheumatoid patients. *Ann Rheum Dis*. 1954;13(1):56-58. [Link](#)
132. West HF, Newns GR. Allergy to bovine ACTH (adrenocorticotrophic hormone). *Lancet*. 1952;262:1308. [Link](#)
133. Zutshi DW, Friedman M, Ansell BM. Corticotrophin therapy in juvenile chronic polyarthritis (still's disease) and effect on growth. *Arch Dis Child*. 1971;46(249):584-593. [Link](#)

Other

Includes MNK-supported non-clinical studies, reviews, mechanism of action and other clinical studies.

134. Aber GM, Chandler GN, Hartfall SJ. Cortisone and A.C.T.H. in treatment of non-rheumatic conditions. *Br Med J*. 1954;1(4852):1-8. [Link](#)

135. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. *Am J Med.* 1999;106(5):534-543. [Link](#)
136. Appel GB, Appel AS. New diagnostic tests and new therapies for glomerular diseases. *Blood Purif.* 2013;35:81-85. [Link](#)
137. Arnason BG, Berkovich R, Catania A, Lisak RP, Zaidi M. Mechanisms of action of adrenocorticotrophic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. *Mult Scler.* 2013;19:130-136. [Link](#)
138. Arya R, Shinnar S, Glauser TA. Corticosteroids for the treatment of infantile spasms: A systematic review. *J Child Neurol.* 2012;27(10):1284-1288. [Link](#)
139. Avelar TN, Hever A, Batech M, et al. Distribution of primary glomerulonephropathies among hispanics [ASN abstract SA-PO839]. *J Am Soc Nephrol.* 2014;25(suppl):831A
140. Baram TZ. What are the reasons for the strikingly different approaches to the use of ACTH in infants with West Syndrome? *Brain and Development.* 2001;7:647-648. [Link](#)
141. Berkovich R, Agius MA. Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis. *Ther Adv Neurol Disord.* 2014;7(2):83-96. [Link](#)
142. Berkovich R. Treatment of acute relapses in multiple sclerosis. *Neurotherapeutics.* 2013;10(1):97-105. [Link](#)
143. Berkovich R, Amezcua L, Subhani D, Cen S. Pilot study of monthly pulse adrenocorticotrophic hormone (ACTH) or methylprednisolone as an add-on therapy to beta-interferons for long-term treatment of multiple sclerosis [AAN abstract]. *Neurology.* 2013;80:e205-e206
144. Berkovich R, Amezcua L, Fernandez M, Subhani D, Kravtsova I. Monthly pulse adrenocorticotrophic hormone (ACTH) or methylprednisolone therapy for long-term treatment of multiple sclerosis as an add-on therapy to beta-interferons: Current status of the pilot study [AAN abstract P04.147]. *Neurology.* 2012;78(suppl 1):22-P04.147
145. Besser GM, Butler PW, Plumpton FS. Adrenocorticotrophic action of long-acting tetracosactrin compared with corticotrophin-gel. *British Medical Journal.* 1967;4(5576):391-394. [Link](#)
146. Bomback AS, Jai R, James EB, et al. The treatment of resistant nephrotic syndrome with Acthar Gel (ACTH) [ASN abstract SA-FC409]. *J Am Soc Nephrol.* 2010;21(suppl):93A
147. Bomback AS, Radhakrishnan, J, Pietro AC, Gerald BA. Treatment of resistant glomerular diseases with ACTH gel: A prospective trial [ASN SA-PO2471]. *J Am Soc Nephrol.* 2011;22(suppl):776A-777A
148. Bomback AS, Radhakrishnan J. Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH). *Discovery Medicine.* 2011;12(63):91-96. [Link](#)
149. Bonkowsky JL, Filloux FM, Byington CL. Herpes simplex virus central nervous system relapse during treatment of infantile spasms with corticotropin. *Pediatrics.* 2006;117(5):e1045-e1048. [Link](#)
150. Brod SA, Hood ZM. Ingested (oral) ACTH inhibits EAE. *J Neuroimmunol.* 2011;232(1-2):131-135. [Link](#)
151. Brod SA, Morales MM. Bio-equivalence of IM and SQ H.P. Acthar Gel. *Biomed Pharmacother.* 2009;63:251-253. [Link](#)
152. Brod SA, Bauer V, Hood Z. Oral ACTH (H.P. Acthar Gel) inhibits IL-1 and IL-17 secretion in humans. *Biomed Pharmacother.* 2012;66(1):36-39. [Link](#)
153. Brunson KL, Khan N, Eghbal-Ahmadi M, Baram TZ. Corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression. *Annals of Neurology.* 2001;49(3):304-312. [Link](#)
154. Cavallari M, Palotai M, Prieto JC, Healy BC, Egorova S, Polgar-Turcsanyi M, Anderson M, Glanz B, Chitnis T, Guttmann CRG. Fatigue predicts conversion to secondary progressive disease phenotype in relapsing-remitting multiple sclerosis patients [ECTRIMS abstract P922]. *Mult Scler.* 2015; 23(sup 11): 46
155. Cheng B, Chou SC, Abraham S, Kowal J. Effects of prolonged ACTH-stimulation on adrenocortical cholesterol reserve and apolipoprotein E concentration in young and aged Fischer 344 male rats. *Journal of Steroid Biochemistry and Molecular Biology.* 1998;66(5-6):335-345. [Link](#)

156. Decker D, Grant C, Oh L, Becker P, Young D, Jordan S. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus. *Lupus*. 2014;23:802-812. [Link](#)
157. Dunagan DP, Rubin BK, Fasano MB. Pneumocystis carinii pneumonia in a child receiving ACTH for infantile spasms. *Pediatr Pulmonol*. 1999;27(4):286-289. [Link](#)
158. Fleischer N, Abe K, Liddle GW, Orth DN, Nicholson WE. ACTH antibodies in patients receiving depot porcine ACTH to hasten recovery from pituitary-adrenal suppression. *J Clin Invest*. 1967;46(2):196-204. [Link](#)
159. Fox RJ, Acot JR, Leshner BA, Malhotra M. Relapse management in RRMS: real-world characteristics of steroid-treated patients [ECTRIMS abstract P670]. *Mult Scler*. 2015; 23(sup 11): 328-329
160. Gentry PA, Liptrap RM, Tremblay RR, Lichen L, Ross ML. Adrenocorticotrophic hormone fails to alter plasma fibrinogen and fibronectin values in calves but does so in rabbits. *Vet Res Commun*. 1992;16(4):253-264. [Link](#)
161. Gitelson S. The effect of ACTH and cortisone on the blood pyruvic acid level. *Acta Endocrinol (Copenh)*. 1954;15(3):225-235. [Link](#)
162. Go T. Sequential MRI in chronic meningitis during adrenocorticotrophic hormone treatment for West Syndrome. *Childs Nervous System*. 2001;17(8):497-499. [Link](#)
163. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. *Nat Rev Nephrol*. 2012;8:122-128. [Link](#)
164. Havrdova E, Bell SJ, Herman DS, Jeffery D, Nicholas JA, Tornatore C. Current MS relapse assessment practices determined by a modified Delphi process [ECTRIMS abstract EP1276]. *Mult Scler*. 2015; 23(sup 11):667
165. Hladunewich MA, Fervenza FC, Beck LH., et al. A pilot study to determine dose, effectiveness and depletion of anti-PLA2R antibodies of adrenocorticotrophic hormone (ACTH Acthar Gel) in subjects with nephrotic syndrome and idiopathic membranous nephropathy (IMN) [ASN abstract FR-OR125]. *J Am Soc Nephrol*. 2012;23(suppl):58A
166. Hogan JJ, Jai R, Gerald BA, Andrew SB, Pietro AC, Maya KR. Treatment of resistant primary focal segmental glomerulosclerosis (FSGS) with adrenocorticotrophic hormone (ACTH) gel [ASN abstract SA-PO381]. *J Am Soc Nephrol*. 2012;23(suppl):725A
167. Kater CE, Irony I, Biglieri EG, Faical S. Continuous adrenocorticotropin administration in hypopituitarism produces asynchronous increases of deoxycorticosterone and 11-deoxycortisol relative to other reduced zona fasciculata steroids. *J Clin Endocrinol Metab*. 1990;71(2):305-310. [Link](#)
168. Khan O, Berkovich R, Hendin B, Javed A, Miller A, Tornatore C. Current practice patterns of MS relapse management among MS specialists in the United States: survey results of the MS relapse practice patterns project [ECTRIMS abstract EP1356]. *Mult Scler*. 2015; 23(suppl 11):709
169. Kongelbeck SR. Discharge planning for the child with infantile spasms. *J Neurosci Nurs*. 1990;No. 4:238-244. [Link](#)
170. Krieger S, Sorrells SF, Nickerson M, Pace TW. Mechanistic insights into corticosteroids in multiple sclerosis: War horse or chameleon? *Clin Neurol Neurosurg*. 2014;119:6-16. [Link](#)
171. Lal R, Bell S, Challenger R, et al. Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone. *J Clin Pharmacol*. 2015:[published online: June 26, 2015]. [Link](#)
172. Landon J, Friedman M, Greenwood FC. Antibodies to corticotrophin and their relation to adrenal function in children receiving corticotrophin therapy. *Lancet*. 1967;1(7491):652-655. [Link](#)
173. Lieberman K, Ettinger L, Picarelli C. ACTH gel for treating steroid resistance (SR) and oral steroid intolerance (OSI) in pediatric minimal change nephrotic syndrome (MCNS) [IPNA abstract P-SUN194]. *Pediatr Nephrol*. 2013;28(8):1598
174. Linden JR, Flores C, Shetty SV, Zhao B, Rumah KR, Ma Y, Vartanian T. In vivo modeling of the nascent multiple sclerosis lesion: epsilon toxin treated mice develop focal demyelinating lesions [ECTRIMS abstract P357]. *Mult Scler*. 2015; 23(sup 11):142-143
175. Loram LC, Culp ME, Connolly-Strong EC, Sturgill-Koszycki S. Melanocortin peptides: Potential targets in systemic lupus erythematosus. *Inflammation*. 2015;38(1):260-271. [Link](#)

176. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: Medical treatment of infantile spasms: Report of the American Academy of Neurology and the Child Neurology Society. *Neurology*. 2004;62(10):1668-1681. [Link](#)
177. Marques N, Sanchez de la Pena S, Ungar F, Halberg F. Circadian stage-dependent effect of ACTH and melatonin on protein synthesis by rat adrenal cells. *Braz J Med Biol Res*. 1988;21(4):759-762. [Link](#)
178. McElhaney JL. Repository corticotropin injection as an adjunct to smoking cessation during the initial nicotine withdrawal period: Results from a family practice clinic. *Clin Ther*. 1989;11(6):854-861. [Link](#)
179. Millar JH, Rahman R, Vas CJ, Noronha MJ, Liversedge LA, Swinburn WR. Effect of withdrawal of corticotrophin in patients on long-term treatment for multiple sclerosis. *Lancet*. 1970;1(7649):700-701. [Link](#)
180. Millar JH, Vas CJ, Noronha MJ, Liversedge LA, Rawson MD. Long-term treatment of multiple sclerosis with corticotrophin. *Lancet*. 1967;2(7513):429-431. [Link](#)
181. Montroy T, Fiechtner JJ. A single-site, investigator initiated, open-label trial of the adrenocorticotrophic hormone (ACTH) analogue HP Acthar Gel (repository corticotropin injection) among subjects with moderately to severely active systemic lupus erythematosus (SLE) [EULAR abstract AB0382]. *Ann Rheum Dis*. 2013;72(suppl 3):904
182. Olsen NJ, Decker DA, Higgins P, et al. Direct effects of H.P. Acthar® Gel on human B lymphocyte activation in vitro. *Arthritis Res Ther*. 2015;17:300. [Link](#)
183. Olsen N, McAloose C, Benko A, Kovacs W, Decker D, Becker P. Repository corticotropin injection (H.P. Acthar® Gel) exerts direct effects on human B cells to suppress IL4/CD40L-stimulated proliferation and immunoglobulin G production in vitro [AAI abstract IRC11P.437]. *J Immunol*. 2015;194(suppl 1):197.19-197.19
184. Parr EJ. Hay fever treated with ACTH gel. *Clin Allergy*. 1976;6(5):479-486. [Link](#)
185. Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: A U.S. consensus report. *Epilepsia*. 2010;51:2175-2189. [Link](#)
186. Quyyum I, Lyman NW, Acthar induced hypokalemic metabolic alkalosis. [ASN abstract FR-PO010] *J Am Soc Nephrol*. 2015; 26 (suppl): 359A.
187. Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M. Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately insured population in the United States [AMCP abstract M14]. *J Managed Care Spec Pharm*. 2015; vol. 21, no. 10-a (suppl): S71.
188. Rosenblum AH, Rosenblum P. Anaphylactic reactions to adrenocorticotrophic hormone in children. *J Pediatr*. 1964;64:387-395. [Link](#)
189. Ross AP, Ben-Zacharia A, Harris C, Smrtka J. Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotrophic hormone. *Front Neurol*. 2013;4:21. [Link](#)
190. Si J, Ge Y, Zhuang S, Wang LJ, Chen S, Gong R. Adrenocorticotrophic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. *Kidney International*. 2013;83(4):635-646. [Link](#)
191. Stafstrom CE, Arnason BG, Baram TZ, et al. Treatment of infantile spasms: Emerging insights from clinical and basic science perspectives. *J Child Neurol*. 2011;26:1411-1421. [Link](#)
192. Tait JF, Tait SA, Bell JB, Hyatt PJ, Williams BC. Further studies on the stimulation of rat adrenal capsular cells: Four types of response. *J Endocrinol*. 1980;87(1):11-27. [Link](#)
193. Tumlin JA, Galphin CM, Rovin BH. Advanced diabetic nephropathy with nephrotic range proteinuria: A pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1. *Journal of Diabetes Research*. 2013:489869. [Link](#)
194. Weaver JA. The therapeutic uses of long acting ACTH. *Scott Med J*. 1978;23(2):153-160. [Link](#)